Table 2 Iron homeostasis biomarkers evaluation in patients with PKD, CDAII, and HS.
From: Evaluation of the main regulators of systemic iron homeostasis in pyruvate kinase deficiency
PKD (N = 41) | CDAII (N = 42) | HS (N = 50) | Pa | Pb | Pc | Controls (N = 25) | |
|---|---|---|---|---|---|---|---|
Hepcidin (ng/mL) | 7.2 (1.3–49.4) | 3.7 (0.3–67.9) | 22.5 (1.6–80.0) | 0.002 | < 0.0001 | 0.0002 | 17.2 (3.0–36.0) |
ERFE (ng/mL) | 18.0 (0.9–108.0) | 24.8 (1.1–70.9) | 9.9 (0.4–266.8) | 0.15 | < 0.0001 | 0.005 | 1.0 (0.3–7.6) |
EPO (IU/L) | 75.6 (12.1–545.0) | 62.7 (19.0–451.0) | 31.6 (9.7–303.7) | 0.44 | 0.0010 | 0.001 | 6.5 (1.9–21.0) |
sTfR (mg/L) | 11.9 (1.9–19.4) | 5.0 (0.8–13.2) | 7.5 (1.1–14.9) | < 0.0001 | 0.004 | 0.002 | 0.7 (0.2–1.5) |
